 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALG-055009 / Aligos Therap
NONCLINICAL TOXICOLOGY PROFILE OF ALG-055009, A NOVEL AND POTENT THYROID HORMONE RECEPTOR Β AGONIST, FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2356;
Combined, this profile indicates ALG-055009 has the potential to be a best-in-class THR-? agonist for the treatment of MASH.
- | ALG-055009 / Aligos Therap
Preclinical, Journal: Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-?) Agonist for the Treatment of MASH. (Pubmed Central) - Sep 2, 2024
agonist. The high metabolic stability and good permeability translated well in vivo to afford a long in vivo half-life pharmacokinetic profile with limited liability for DDI, and it overcomes certain drawbacks seen in recent clinical candidates.
- |||| ALG-055009 / Aligos Therap
New P2 trial: ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (clinicaltrials.gov) - Apr 2, 2024
P2, N=100, Recruiting, Sponsor: Aligos Therapeutics
- ALG-055009 / Aligos Therap
Pharmacodynamics of multiple oral doses of ALG-055009, a THR? agonist, in hyperlipidemic subjects (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_2134;
P1
The high metabolic stability and good permeability translated well in vivo to afford a long in vivo half-life pharmacokinetic profile with limited liability for DDI, and it overcomes certain drawbacks seen in recent clinical candidates. Favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and SHBG were observed with multiple dosing of ALG-055009 in HL subjects.
- || ALG-055009 / Aligos Therap
New P1 trial: A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) (clinicaltrials.gov) - Jan 5, 2024
P1, N=27, Active, not recruiting, Sponsor: Aligos Therapeutics
- ||| ALG-055009 / Aligos Therap
Trial completion, Enrollment change: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia (clinicaltrials.gov) - Sep 25, 2023
P1, N=98, Completed, Sponsor: Aligos Therapeutics
Favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and SHBG were observed with multiple dosing of ALG-055009 in HL subjects. Active, not recruiting --> Completed | N=152 --> 98
- ALG-055009 / Aligos Therap
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-?) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia (2nd floor Poster Area - 244) - Feb 15, 2023 - Abstract #APASL2023APASL_932;
P1
Consistent with a thyromimetic mechanism of action, ALG-055009 resulted in dose-dependent, transient increases in SHBG as well as decreases in thyroid hormones and atherogenic lipids. 909
- || ALG-055009 / Aligos Therap
Enrollment closed, Trial completion date, Trial primary completion date: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia (clinicaltrials.gov) - Nov 16, 2022
P1, N=152, Active, not recruiting, Sponsor: Aligos Therapeutics
909 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Jun 2023
- ALG-055009 / Aligos Therap
SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING ORAL DOSES OF ALG-055009, A THYROID HORMONE RECEPTOR BETA AGONIST, IN HYPERLIPIDAEMIC SUBJECTS. () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1133;
P1
Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Jun 2023 In HL subjects, multiple daily doses of up to 0.6 mg ALG-055009 given for 14 days were well tolerated with a predictable PK profile.
- ALG-055009 / Aligos Therap
Safety and pharmacokinetics (PK) of single and multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist for the treatment of non-alcoholic steatohepatitis (NASH) , in healthy volunteers and subjects with hyperlipidemia (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2244;
P1
In HL subjects, multiple daily doses of up to 0.6 mg ALG-055009 given for 14 days were well tolerated with a predictable PK profile. Single doses of ALG-055009 of up to 4 mg and multiple daily 0.3 mg doses for 14 days were well tolerated with a favourable PK profile.
- ||| ALG-055009 / Aligos Therap
Enrollment open: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia (clinicaltrials.gov) - Jan 11, 2022
P1, N=152, Recruiting, Sponsor: Aligos Therapeutics
Single doses of ALG-055009 of up to 4 mg and multiple daily 0.3 mg doses for 14 days were well tolerated with a favourable PK profile. Not yet recruiting --> Recruiting
- ||| ALG-055009 / Aligos Therap
New P1 trial: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia (clinicaltrials.gov) - Oct 21, 2021
P1, N=152, Not yet recruiting, Sponsor: Aligos Therapeutics